What is C4 Therapeutics, Inc's P/S Ratio?

C4 Therapeutics, Inc (CCCC) P/S Ratio is 11.15x based on the latest available daily valuation data on Chartloom.

How to interpret P/S Ratio for C4 Therapeutics, Inc?

Interpreting P/S Ratio for C4 Therapeutics, Inc depends on industry, growth expectations, profitability, and peer multiples.

High P/S ratios reflect expectations for future margin expansion or rapid growth.

Compare to peers with similar gross-margin profiles.

P/S ignores profitability and capital structure, making it a simple but blunt valuation tool.

Please enable JavaScript to continue using this application.

P/S Ratio = Market Capitalization / Revenue (TTM)

Market capitalization divided by trailing twelve-month revenue. A valuation metric often used when earnings are negative or not meaningful.

Latest P/S Ratio

11.15x

As of Oct 9, 2026

P/S Ratio

Beyond P/S Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.

Recent P/S Ratio history

Daily readings for the most recent trading days on record.

How is P/S Ratio calculated?

Peers of C4 Therapeutics, Inc (CCCC)

Side-by-side comparison

C4 Therapeutics, Inc (CCCC) Historical P/S Ratio | 2016-2026